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Abstract
Objectives: Epidemiological evidence for associations of Anti-Mu¨llerian hormone (AMH) with cardiometabolic risk factors is
lacking. Existing evidence comes from small studies in select adult populations, and findings are conflicting. We aimed to
assess whether AMH is associated with cardiometabolic risk factors in a general population of adolescent females.
Methods: AMH, fasting insulin, glucose, HDLc, LDLc, triglycerides and C-reactive protein (CRP) were measured at a mean age
15.5 years in 1,308 female participants in the Avon Longitudinal Study of Parents and Children (ALSPAC). Multivariable linear
regression was used to examine associations of AMH with these cardiometabolic outcomes.
Results: AMH values ranged from 0.16–35.84 ng/ml and median AMH was 3.57 ng/ml (IQR: 2.41, 5.49). For females classified
as post-pubertal (n = 848) at the time of assessment median (IQR) AMH was 3.81 ng/ml (2.55, 5.82) compared with 3.25 ng/
ml (2.23, 5.05) in those classed as early pubertal (n = 460, P#0.001). After adjusting for birth weight, gestational age,
pubertal stage, age, ethnicity, socioeconomic position, adiposity and use of hormonal contraceptives, there were no
associations with any of the cardiometabolic outcomes. For example fasting insulin changed by 0% per doubling of AMH
(95%CI: 23%,+2%) p = 0.70, with identical results if HOMA-IR was used. Results were similar after additional adjustment for
smoking, physical activity and age at menarche, after exclusion of 3% of females with the highest AMH values, after
excluding those that had not started menarche and after excluding those using hormonal contraceptives.
Conclusion: Our results suggest that in healthy adolescent females, AMH is not associated with cardiometabolic risk factors.
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Introduction
Anti-Mu¨llerian hormone (AMH) is increasingly recognised as a
biomarker of the ovarian reserve in adults, due to its strong
correlation with primordial follicle number, [1] follicular recruit-
ment rates, [2] response to exogenous gonadotrophins [2] and
ability to predict the duration of the reproductive lifespan. [3] In
children, similar associations between AMH and the ovarian
reserve have been observed. Specifically, girls with a reduced
ovarian reserve and shorter reproductive lifespan due to Turners
syndrome have low AMH levels, [4] in prepubertal and
peripubertal girls AMH levels reflects follicular recruitment rates,
[2,5] and as observed in adults, AMH is negatively associated with
follicle stimulating hormone (FSH) in girls from 5 to 15 years. [6]
Collectively these studies suggest that AMH may be a useful
surrogate of the ovarian reserve and follicular recruitment
throughout life.
Premature ovarian insufficiency has been associated with
abnormal cardiovascular risk factors and increased cardiovascular
mortality [7–9]. Ovarian decline and its sequelae are however
increasingly being viewed as a continuum rather than an abrupt
event at the time of menopause. Investigation of the nature of the
relationship between ovarian aging and cardiovascular risk in
premenopausal women, has been more limited, but has demon-
strated that atherosclerotic lesions predate the onset of the
menopause, [10] and that women with reduced ovarian reserve
as detected by an elevated FSH but normal oestrogen concentra-
tions exhibit abnormal lipid profiles. [11] The stronger relation-
ship between AMH and ovarian reserve than that observed of the
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latter with FSH, [1] has consequently led to AMH being examined
in adults relative to established cardiometabolic risk factors,
including lipids, insulin, C-reactive protein (CRP) and body mass
index (BMI),[12–23] and in animal models, with atherosclerosis
plaque size. [24] These studies have produced conflicting results;
for example the association of AMH with insulin has been
reported as being positive, [20,25] negative, [26,27] or null. [28]
This discordance may potentially reflect the relatively small
sample sizes studied and the use of select populations, such as
women with PCOS. [20,25,27] Furthermore, there may be
confounding by factors such as smoking and socioeconomic status,
[29,30] or bias due to reverse causality with compromised ovarian
vascular function adversely impacting on AMH concentrations.
[31].
It would therefore be valuable to study the associations of AMH
with cardiometabolic factors in a large, well phenotyped cohort of
women from the general population and without established
disease. Doing this in a young (adolescent) age group would be
valuable because at this age associations are less likely to be
confounded by behavioural lifestyle characteristics such as
smoking or subject to bias, for example by reverse causality, as
atherosclerosis at this age is rare. Furthermore, both mathematical
modelling of cross-sectional data and prospective longitudinal data
have suggested that AMH is relatively stable at this age, [4,32,33]
and importantly these cardiometabolic risk factors in adolescence
are indicators of future cardiovascular risk. In postmortem studies
they have been related to extent of clinically relevant arthero-
sclerosis. [34] Blood pressure in adolescence/early adulthood has
been shown to relate to future cardiovascular disease mortality
with similar magnitudes of association to those seen for blood
pressure in middle age, [35] and blood pressure, markers of
dysglycaemia and dyslipidaemia in childhood/adolescence are
associated with carotid intima media thickness in mid-adulthood
with similar magnitudes of association to the same risk factors
measured at the same time as carotid intima media thickness.
[36,37].
The aim of this paper is to examine associations of AMH with
fasting insulin, glucose, lipids and CRP in a general population of
females with a mean age of 15.5 years.
Subjects and Methods
Ethical approval for the study was obtained from the Avon
Longitudinal Study of Parents and Children Law and Ethics
Committee (IRB# 00003312) and the Local Research Ethics
Committees (Bristol and Weston, Southmead, and Frenchay
Health Authorities). Written informed consent was obtained from
all participants in the study. Parents provided written informed
consent for their child.
Study Population
The Avon Longitudinal Study of Parents and Children is a
population-based, prospective birth cohort, investigating factors
that affect the health and development of children. Detailed
methods of ALSPAC have been described previously, [38,39] and
are on the study website (www.alspac.bris.ac.uk). Briefly, 14,541
pregnant women resident in the Bristol area with an expected date
of delivery between 1st April 1991 and 31st December 1992 were
enrolled into the cohort, and of these, 13,988 had a live-born child
who was still alive at age 1 year. Participants who attended the 15
year follow-up clinic and who had data on AMH were eligible for
inclusion in our study (n= 1,781). Our study sample consists of
1,308 female adolescents (13 sets of twins) who had complete data
on AMH, cardiometabolic outcomes and all potential confounders
(see Figure 1). Ethical approval was obtained from the ALSPAC
Law and Ethics committee and relevant local ethics committees in
line with the Declaration of Helsinki, and written informed
consent was provided by all participants.
Assessment of Serum AMH
For all blood measures, participants were asked to fast overnight
if attending the morning clinic, or for a minimum of 6 hours if
attending after lunch. All blood samples were immediately spun
and frozen at 280uC. Assays were completed on serum using the
commercial AMH generation II ELISA kit provided by Beckman
Coulter (Beckman Coulter UK Ltd, High Wycombe, UK). [40]
Inter and intra-assay CVs were both ,5%.
Assessment of Outcomes
Serum insulin was measured with an enzyme linked immuno-
sorbent assay (ELISA, Mercodia, Uppsala, Sweden) that does not
cross-react with proinsulin. Plasma glucose and CRP were
measured with an automated assay, the latter with excellent
sensitivity down to 0.1 mg/l. Plasma triglyceride, total cholesterol
and HDL-c concentrations were measured by modification of the
standard Lipid Research Clinics Protocol by using enzymatic
reagents for lipid determination, and LDL-c concentration was
determined from these, using the Friedwald equation. [41] Inter
and intra-assay CVs for lipids, glucose and CRP were all ,5%.
For insulin, inter-assay CV is ,9.3% and intra-assay CV were
,6.0%. It has been established in children and adults that fasting
insulin is very highly correlated with formulae that attempt to
more accurately measure insulin resistance, such as HOMA-IR or
QUICKI, by combining fasting glucose and insulin. [42,43] A
recent consensus statement recommends that fasting insulin be
used (rather than HOMA-IR or QUICKI) in epidemiological
studies of children/adolescents. [44] In our sample fasting insulin
was very highly correlated with HOMA-IR (Pearson’s correlation
coefficient 0.98) and QUICKI (0.97) and all results were identical
if either of these were used in place of fasting insulin. We therefore
present only results with fasting insulin.
Figure 1. Participant flow through the study. *Participants who
had withdrawn, were lost to follow-up or had died were not invited.
doi:10.1371/journal.pone.0064510.g001
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Assessment of Potential Confounders
The following were considered as potential confounders: birth
weight, gestational age, pubertal stage, age, age at menarche,
ethnicity, socioeconomic position, adiposity, level of physical
activity, smoking status and the use of hormonal contraceptives.
Birth weight was recorded in the delivery room and abstracted
from obstetric records and/or birth notifications. Gestational age
was abstracted from clinical records. Pubertal staging was assessed
by annual questionnaires which were mailed to participants from
age 8 to age 17. The puberty questionnaire could be answered by
the participant, a parent, a guardian, or any combination of these
individuals. On each questionnaire, the respondent was asked to
examine line drawings representing the five Tanner stages for
breast size and for pubic hair and to record which drawing most
nearly represented the participant’s current stage of development.
[45,46] In each questionnaire, the participant was also asked
whether she had had her first menstrual period and, if so, the
month and year in which it occurred. Pubertal stage at the time of
AMH measurement was established by taking the highest self-
reported Tanner rating for either breast development or pubic
hair, and using whichever was available if one of these was
missing. [45] Whether the participant had started menstruating
and if so, at what age this occurred was reported by the participant
or her mother in questionnaires administered repeatedly between
age 97 and 192 months. The small number of participants who
had still not started menstruating at the time of the last
questionnaire (N = 6 (0.46%)) were allocated an age of menarche
of 204 months (17 years) in order to allow all participants to be
included in analyses. Age was recorded at the time of clinic
assessment. Ethnicity was based on the mother’s and her partner’s
ethnicity as reported by the mother. Fat mass was measured using
a Lunar Prodigy Dual-energy X-ray absorptiometry (DXA)
scanner (GE Medical Systems Lunar, Madison, WI). Scans were
visually inspected and realigned where necessary. Height was
measured to the nearest 0.1 cm with a Harpenden stadiometer
with the participant unshod. To assess physical activity, all
participants attending the clinic were asked to wear an Actigraph
accelerometer (Actigraph LLC, Fort Walton Beach, Florida) for
seven days. Data from participants who had worn the Actigraph
for at least ten hours per day for at least three days were
considered valid. [47] Two main physical activity variables were
derived; average accelerometer counts per minute (CPM) over the
full period of valid recording, and average number of minutes in
moderate to vigorous physical activity (MVPA), per valid
measurement day. [48] Based on questionnaire responses, the
highest parental occupation was used to allocate participants to
family social class groups using the 1991 British Office of
Population and Census Statistics (OPCS) classification. Partici-
pants were asked about their smoking habits by questionnaire at
mean age 14.3 years (the questionnaire administered closest to,
and before, the time of the assessment where blood samples were
taken) and these data were used to generate a three-level
categorical smoking variable: ‘none’ (including those who have
never tried a cigarette and those who used to smoke sometimes,
but never smoke now), ‘,1 cigarette per week’ or ‘.1 cigarette per
week’. Information on use of the hormonal contraceptive pill in
the last year was asked in a single question, administered at the
same time as the assessment where blood samples were taken. This
question was answered by 1,283 (98%) of our study sample. Of the
25 study participants who did not answer this question, 13
indicated in a separate question concerned with recent sexual
activity that they were taking the pill, and a further 12 who did not
answer either of these questions had an assay result for sex
hormone binding globulin (SHBG) .100 nmol/l, which was
considered to indicate use of hormonal contraceptives.
Statistical Analysis
All analyses were conducted in Stata/MP 11.2 (StataCorp,
College Station, Texas). AMH, fasting insulin, triglycerides and
CRP were positively skewed. In descriptive analyses medians and
interquartile ranges (IQR) are presented for these variables, and
their natural logs were used in regression models; residuals in these
models were approximately normally distributed after these
transformations. Consistent with the age of assessment, there were
no participants in Tanner stages 1 and 2, and few participants in
Tanner stage 3 (Table 1). Therefore we generated a binary
variable categorising Tanner stage 5 as post-pubertal and stages 1–
4 as early pubertal.
In order to examine whether there were non-linear associations
of AMH with outcomes and to ensure correct modelling of
potential confounding factors, distributions of outcomes and
confounders were examined by quintiles of AMH and tests of
linear associations and deviation from linearity were computed.
The first was obtained from a model in which AMH quintiles were
entered as a continuous variable and the latter from comparing the
linear model to a model in which AMH quintiles were included as
four indicator variables using a likelihood ratio test.
A series of multivariable linear regression models were used to
examine associations of AMH with each outcome. The crude
association is estimated in Model 1. We then adjusted for age,
pubertal stage, age at menarche, ethnicity, socioeconomic position,
fat mass, height, height-squared, and hormonal contraceptive use
(Model 2). The inclusion of height and height-squared as
covariables in the analyses that included fat mass was to ensure
adjustment for greater relative adiposity, rather than greater fat
mass as a result of greater height. To make coefficients from
multivariable regression models more interpretable, they were
multiplied by log base 2 so that results are the mean difference in
outcome per doubling of AMH. For outcomes that were logged
(fasting insulin, triglycerides and CRP) regression coefficients were
back transformed (exponentiated) so that coefficients represent the
percentage change in the outcome per doubling of AMH. Analyses
were conducted on all participants in our study sample including
those taking the hormonal contraceptive pill, with hormonal
contraceptive use being adjusted for in the regression model
(n = 1,308). Analyses were then repeated after excluding the 170
(13%) participants taking the hormonal contraceptive pill.
Sensitivity Analyses
Smoking, physical activity and age at menarche were consid-
ered as potential confounders. However, there were variable
amounts of missing data for each of these confounder; for smoking
data was available for 1,096 [83.8%] of those with complete data
on all other variables; physical activity data available for 607
[46.4%]; and age at menarche data for 1,191 [91.1%]. To assess
potential confounding by these variables we completed sensitivity
analyses on the sub-samples for who these data were available. We
compared models 1 and 2 in these subsets with equivalent results
from the larger main sample of 1,308. We then adjusted for
smoking, physical activity and age at menarche in a group of final
models (Model 3a, 3b and 3c, respectively). To ensure that females
with exceptionally high AMH values were not driving any of the
observed associations, we repeated all analyses excluding those
females within the highest 3% of the AMH distribution (i.e. over 2
standard deviations above the mean AMH level, N= 63). We also
repeated analyses after excluding the 6 (0.46%) participants who
AMH and Cardiometabolic Risk Factors
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had not yet started menarche, as this small group could potentially
be experiencing delayed puberty.
Results
Table 1 summarises the characteristics of our analysis sample
(n = 1,308) and also of those female participants who were eligible
but were excluded from the analysis due to missing data for
potential confounders or cardiometabolic outcomes. Excluded
participants had, on average, higher insulin, glucose and LDLc
than those who were included. Participants who were excluded
were also more likely to be older, have a later age at menarche, of
non-white ethnicity, taking hormonal contraceptives, and less
likely to be post-pubertal. However, for most of these character-
istics the magnitude of the differences was small.
Table 1. Characteristics of participants included in the study (n = 1,308), and excluded due to missing data (n = 473).
Included participants (total n =1,308) Excluded participants**(total n=473) P
N with available
data Distribution
N with available
data*** Distribution
Median AMH (ng/ml) (IQR) 1,308 3.57 (2.41, 5.49) 473 3.77 (2.60, 5.62) 0.13*
Outcomes
Median fasting insulin-iu/l (IQR) 1,308 9.72 (7.39, 12.79) 471 10.31 (7.51, 14.08) ,0.01*
Mean glucose - mmol/l (SD) 1,308 5.12 (0.34) 471 5.18 (0.49) ,0.01
Mean HDLc - mmol/l (SD) 1,308 1.36 (0.30) 471 1.33 (0.29) 0.11
Mean LDLc - mmol/l (SD) 1,308 2.16 (0.56) 471 2.23 (0.62) 0.04
Median triglycerides - mmol/l (IQR) 1,308 0.76 (0.62, 0.98) 471 0.79 (0.62, 1.04) 0.11*
Median CRP - mg/l (IQR) 1,308 0.39 (0.22, 0.86) 471 0.43 (0.22, 1.07) 0.08*
Potential confounders
Mean birth weight in kg (SD) 1,308 3.38 (0.48) 355 3.37 (0.57) 0.80
Mean gestational age in weeks, (SD) 1,308 39.60 (1.66) 386 39.43 (1.93) 0.10
Mean z-score of fat mass 1,308 0.02 (0.96) 351 0.07 (1.08) 0.46
Non-white (%) 1,308 45 (3.44) 294 21 (7.14) ,0.01
Non-manual social class (%) 1,308 1,127 (86.16) 473 413 (87.32) 0.53
Mean age in years (SD) 1,308 15.41 (0.27) 468 15.65 (0.50) ,0.001
Taking hormonal contraceptives (%) 1,308 170 (13%) 304 79 (26%) ,0.001
Body mass index category (%)
Underweight 1,308 82 (6.27) 439 30 (6.83) 0.29
Normal weight 957 (73.17) 305 (69.48)
Overweight 212 (16.21) 76 (17.31)
Obese 57 (4.36) 28 (6.38)
Pubertal stage**** (%)
Stage 1 1,308 0 350 1 (0.29) 0.04
Stage 2 0 1 (0.29)
Stage 3 24 (1.83) 10 (2.86)
Stage 4 436 (33.33) 124 (35.43)
Stage 5 848 (64.83) 214 (61.14)
Covariables additionally adjusted for
in the sensitivity analyses
Median CPM (IQR) 607 420.58 (339.33, 511.12) 142 425.60 (350.32, 523.85) 0.66*
Median MVPA (IQR) 607 15.14 (7.57, 27.00) 142 15.55 (8.66, 29.71) 0.88*
Ever smoked (%) 1,096 336 (30.57) 305 95 (31.15) 0.85
Median age at menarche in years (IQR) 1,191 12.83 (11.83, 13.67) 335 13.00 (11.75, 13.83) ,0.01*
IQR – interquartile range. SD – standard deviation.
For continuous variables the difference between the means of those included and excluded from the analysis was tested using an unpaired t-test.
For categorical variables the difference between those included and excluded from the analysis was tested using Pearson’s chi-squared test.
*For non-normally distributed variables, differences between medians of those included and excluded from the analysis were tested using a Mann-Whitney U-test.
**Excluded participants are those that were eligible for inclusion in our study (i.e. they attended the 15 year and had data on AMH), but who were missing data for
cardiometabolic outcomes and/or potential confounders.
***The ‘N with available data’ for the excluded participant’s column relates to the number of excluded participants that had data for each of the variables included in
our analysis. Thus, the means, medians and percentages reported for the excluded participants are based only on those that had data available for each variable.
****The highest pubertal stage was established by taking the highest Tanner rating for either breast development or pubic hair. If there were missing data for breast
development, pubic hair ratings were used where available and vice versa
doi:10.1371/journal.pone.0064510.t001
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AMH values ranged from 0.16–35.84 ng/ml and median AMH
was 3.57 ng/ml (IQR: 2.41, 5.49). For females classified as post-
pubertal, median (IQR) AMH was 3.81 ng/ml (2.55, 5.82)
compared with 3.25 ng/ml (2.23, 5.05) in those classed as in
early puberty (P value from a Mann-Whitney U-test of the
difference between median AMH levels in the two puberty
categories #0.001).
Table 2 shows the distributions of cardiometabolic outcomes
and confounders by quintiles of AMH. There was some evidence
of an inverse linear association of AMH with CRP and age at
menarche, and that the association with DXA determined fat mass
deviated from linearity; however, BMI and percentages of
overweight and obese did not differ relative to quintiles of
AMH. There was no strong evidence that the distribution of other
outcomes or confounders varied across quintiles of AMH.
Multivariable associations of AMH with all outcomes are
displayed in Table 3. After adjustment for confounders, AMH
was not associated with any of the cardiometabolic outcomes.
Results did not change substantially after the 170 (13%)
participants taking hormonal contraceptives were removed from
the analyses (Table 4). The percentage change coefficient for the
association between AMH and CRP changed direction (23%,
95%CI 28% to+2% in the analysis including those that were
taking hormonal contraceptives compared to+1%, 95% CI 25%
to+7% when participants taking hormonal contraceptives were
excluded). However, neither of these associations reached the
conventional 5% significance level.
Sensitivity Analyses
Table S1–S3 show the multivariable analyses of AMH with
cardiometabolic outcomes in the subgroup of participants who
additionally had complete data on smoking, physical activity and
age at menarche, respectively. Results did not differ substantially
in the subgroups with smoking, physical activity and age at
menarche data to those in the main analysis shown in Table 2.
This suggests that missing data for these potential confounding
factors did not result in selection bias. Additional adjustment for
smoking, physical activity or age at menarche did not alter results.
Results were largely unchanged when females in the highest 3% of
the AMH distribution were excluded (Table S4) or when those
that had not started menarche were excluded (Table S5).
Discussion
In this study we demonstrated that AMH was not associated
with a range of cardiometabolic risk factors including lipids and
insulin in a large general population of adolescent females. In
accordance with recent longitudinal and cross-sectional studies,
[32,33,49] we identified that AMH levels were slightly higher in
females assessed post-puberty, compared with those assessed
during early puberty, however adjusting for pubertal status did
not alter the lack of association of AMH with cardiometabolic risk
factors.
Although we have modelled AMH as the exposure and the
cardiometabolic risk factors as the outcomes, given that they are
measured at the same time their respective classification as
exposure and outcome are interchangeable. Whilst studies of this
association to date (see introduction) have been interpreted as
examining the hypothesis that more rapid ovarian ageing (that
AMH proxies for) may be associated with more adverse
cardiometabolic outcomes, the opposite has also been proposed.
Hyperinsulinaemia has been proposed as a possible mechanism
that may disrupt normal follicular development, [50] with
polycystic ovary syndrome associated with both hyperinsulinaemia
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and marked increases in AMH, [20,25] however in the current
study we did not see an association between AMH and insulin, and
there was also no evidence of a non-linear association suggestive of
a threshold effect.
We are aware of only one other study that has examined the
association of AMH with CRP, in adult Asian women (n = 290).
[51] In that study of a mixed population of women with and
without PCOS, consistent with our own findings, no overall
association across the distributions of both AMH and CRP was
observed. Lin et al reported AMH to be positively associated with
total cholesterol, both HDL-C and LDL-C in a mixed population
of women with and without PCOS, but this finding was not
replicated in an analysis of adult ovulatory women. [52]
Furthermore in an animal model of atherosclerosis, AMH was
not associated with lipid concentrations. [24] Further large studies
are required to ascertain whether AMH is associated with an
adverse lipid profile in adolescents.
Our null results could be because there is, in fact, no association
of AMH with cardiometabolic outcomes, and the contradictory
results in select adult women to date represent the expected
variation around a true null association. It is also possible that
associations observed in previous studies are explained by
confounding, either because they did not appropriately adjust
for confounders such as socioeconomic position or fat mass, or
because they had inadequate measurements of potential con-
founders. It is notable that in our study of adolescent females,
where confounding by characteristics such as smoking or an effect
of existing undiagnosed atherosclerosis on AMH is highly unlikely,
we did not observe an association even before multivariable
adjustment for potential confounders. In previous publications we
have shown expected associations with fasting insulin, glucose and
the other cardiovascular risk factors examined here, for example
we have shown a dose response association of BMI, waist
circumference and total body fat mass with these outcomes, [53]
illustrating that the null results presented here are highly unlikely
to be due to error in the outcome measurements. It is possible that
associations of AMH with cardiometabolic outcomes emerge only
at a later age and/or exist only in sub-groups of the population
such as those with PCOS. Future prospective studies with AMH
and cardiovascular risk factors in adult premenopausal women are
needed to ascertain whether ovarian reserve is independently
associated with cardiovascular risk over the established associa-
tions with oestrogen production. Overall our findings raise the
possibility that functional ovarian reserve as assessed by AMH is
Table 3. Multivariable associations of AMH with cardiometabolic risk factors (n = 1,308).
Model 1 Model 2
Coeff 95% CI P Coeff 95% CI P
Mean difference per doubling of AMH
Glucose mmol/l 20.003 20.02, 0. 02 0.73 20.004 20.02, 0.01 0.64
HDL-c mmol/l 20.004 20.02, 0.01 0.63 20.006 20.02, 0.009 0.42
LDL-c mmol/l 0.004 20.03, 0.03 0.79 0.01 20.02, 0.04 0.43
Ratio of geometric means per doubling of AMH
Insulin iu/l 21% 23%,+2% 0.56 21% 23%,+2% 0.56
Triglyceride mmol/l 0% 22%,+2% 0.74 0% 22%,+2% 0.94
CRP mg/l 24% 29%,+2% 0.19 23% 28%,+2% 0.22
Model 1– crude estimate.
Model 2– additionally adjusted for birth weight, gestational age, pubertal stage, age, age at menarche, ethnicity, socioeconomic position, fat mass, height and height2
and use of the hormonal contraceptive pill.
doi:10.1371/journal.pone.0064510.t003
Table 4. Multivariable associations of AMH with cardiometabolic risk after excluding 170 (13%) participants taking the hormonal
contraceptive pill (n = 1,138).
Model 1 Model 2
Coeff 95% CI P Coeff 95% CI P
Mean difference per doubling of AMH
Glucose mmol/l 20.01 20.03, 0.007 0.19 20.01 20.03, 0.008 0.23
HDL-c mmol/l 20.003, 20.02, 0.01 0.72 20.004 20.02, 0.01 0.65
LDL-c mmol/l 0.006 20.03, 0.04 0.71 0.01 20.02, 0.01 0.52
Ratio of geometric means per doubling of AMH
Insulin iu/l 21% 23%,+2% 0.63 21% 23%,+2% 0.53
Triglyceride mmol/l 0% 22%,+2% 0.99 0% 22%,+2% 0.85
CRP mg/l +2% 24%,+8% 0.61 +1% 25%,+7% 0.73
Model 1– crude estimate.
Model 2– additionally adjusted for birth weight, gestational age, pubertal stage, age, age at menarche, ethnicity, socioeconomic position, fat mass, height and height2.
doi:10.1371/journal.pone.0064510.t004
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not a direct determinant of the lipid and insulin cardiometabolic
risk profile during the early reproductive years in healthy women.
Strengths and Limitations
To our knowledge, this is the largest study to date to examine
associations of AMH with a range cardiometabolic factors in a
general adolescent female population. The cross-sectional design
does not allow us to establish causality or the direction of
association. Some potential confounders (smoking, physical
activity and age at menarche) were only available in subgroups
of participants, but analyses in these subgroups did not suggest
they were importantly different from the main analysis sample or
that these characteristics were important confounders. As is
common in birth cohort studies there has been loss to follow-up
over time (Figure 1) and participants who were excluded from our
study because of missing data differed slightly for some charac-
teristics compared to those who were included (Table 1). Our
results would only be biased if associations were markedly different
in those lost to follow-up or with missing data compared to those
included in our analyses, and whilst we cannot test this, we cannot
think of any reason as to why this would be the case. Consistent
with other large epidemiological studies conducted in general
population samples; we are not able to directly measure insulin
resistance using the gold standard euglycaemic hyperinsulinemic
clamp. Fasting insulin has been shown to have modest to strong
correlations with clamp assessed insulin resistance (correlation
coefficients 0.5 to 0.9) in children and adolescents. [42] Any
measurement error is likely to be non-differential and therefore
would be expected to bias results towards the null. However, even
if non-differential measurement error resulted in our associations
being weaker than they would be with a direct measure of insulin
resistance, with correlations of 0.5 to 0.9 we would have expected
some association of AMH with fasting insulin if this were an
important determinant and/or predictor. For this study we were
unable to conduct physical assessments of pubertal development
by trained clinical personnel. In the absence of a direct visual
assessment by a clinician, self-assessment of Tanner stage is
considered a practical and valid choice, particularly for longitu-
dinal studies with repeat assessments. [54] Kappa coefficients
comparing clinician to self-assessments range from 0.3 to 0.9 for
breast and from 0.4 to 0.9 for pubic-hair development in different
studies. [55] Our study used the drawings of pubertal stages
developed by Morris and Udry, [46] which had been successfully
used in previous cohort studies. [56,57] We do not have diagnostic
information on whether female participants had PCOS; however
removing participants with an AMH .2 standard deviations from
the mean (the highest 3% of the AMH distribution) did not change
any associations. We adopted this approach as the adult diagnostic
criteria for PCOS has recently been recognised as not appropriate
for adolescent girls, [58] although AMH is elevated in adolescents
with polycystic ovarian morphology and in PCOS. [59] We also
do not have measures of testosterone and could therefore not
investigate the association between androgens and AMH. Lastly
our population are largely of European, white ethnic origin and we
cannot assume that results would generalise to other ethnicities.
In conclusion, we have found that in a general population of
adolescent females, AMH is not associated with fasting insulin or
other cardiometabolic outcomes. There is a need for further large
prospective studies of these associations that include repeat
measurements with increasing age in order to understand whether
AMH, a marker of ovarian reserve, is importantly related to
cardiometabolic health in healthy women as they age from early
adolescence to peak reproductive age and beyond.
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